Compare Garmin Ltd. (GRMN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs State Street SPDR S&P Biotech ETF — how do they compare? Garmin Ltd. trades at $250.08 (market cap $46.62B), while State Street SPDR S&P Biotech ETF trades at $151.59. The key difference: Garmin Ltd. pays a 1.74% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| GRMN | XBI | |
|---|---|---|
Market Cap | $46.62B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $267.52 | $164.28 |
52-Week Low | $187.10 | $85.16 |
Enterprise Value | $44.09B | — |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $247.96, up 2.72% on the day, with a neutral technical outlook and mixed earnings history including recent beats. Revenue growth is strong, reaching $7.25B in 2025, with robust profitability margins. Recent news highlights product innovations in aviation and marine electronics, supporting growth prospects. The stock is near its consensus price target of $281.50, indicating moderate upside potential from current levels.
The outlook for GRMN is cautiously optimistic, driven by solid fundamentals and innovation, but tempered by high valuation ratios and a majority hold rating from analysts. Key risks include competitive pressures and market volatility, while institutional sentiment remains mixed with limited insider activity noted.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
